GMP Manufacturing for Peptide and Oligonucleotide Therapeutics – Ensuring Quality and Scale

In today’s biotech landscape, quality is essential. Good Manufacturing Practice (GMP) guidelines are the cornerstone of safe, effective, and consistent pharmaceutical production. For TIDES therapeutics, many of which treat complex or life-threatening conditions, GMP compliance is not just a requirement; it is a foundational element of regulatory approval and patient trust.

This article explores how GMP standards guide the production of these advanced therapies, what makes TIDES manufacturing uniquely challenging, and why aligning with a GMP-experienced manufacturer is essential for therapeutic success.

The Growing Importance of Peptide and Oligonucleotide Therapeutics

Peptides and oligonucleotides are transforming modern medicine. Peptide-based drugs have become the fastest-growing segment of chemically synthesized therapeutics, with over 80 approved worldwide, more than 200 in clinical development, and hundreds more in preclinical stages (Rossino et al., 2023). Oligonucleotide therapies, such as antisense and siRNA-based drugs, have also seen significant growth, with more than 20 US and EU approved products to date (Vinjamuri et al., 2024). In 2024, four of the 50 novel drugs approved by the U.S. FDA were either peptide or oligonucleotide therapies, clear evidence of their growing clinical and commercial relevance (Al Musaimi et al., 2024).

This surge in innovation creates demand for highly specialized manufacturing environments. Unlike traditional small molecules, TIDES are large, complex structures that require precise synthesis and purification. Scaling from research quantities to kilogram clinical supply demands both technical mastery and strict GMP compliance. Regulatory authorities worldwide expect manufacturers to demonstrate control, traceability, and reproducibility at every stage.

Understanding GMP Standards in Pharmaceutical Manufacturing

As defined by global regulatory agencies such as the FDA, EMA, and NMPA, GMP ensures that medicines are consistently produced and controlled to quality standards. It covers every step of manufacturing, from raw materials and cleanroom environments to equipment, training, and documentation, to safeguard patient safety and ensure each product is traceable, consistent, and compliant.

Facilities that meet GMP expectations operate under defined procedures, investigate deviations, and document all operations using ALCOA principles: data must be Attributable, Legible, Contemporaneous, Original, and Accurate (MHRA, 2018).

Why GMP Matters in TIDES Manufacturing

Peptides and oligonucleotides are highly sensitive to variations in manufacturing. These therapies are often delivered via injection, requiring high purity and sterility (DeCollibu et al., 2023). Multi-step synthesis processes such as SPPS and phosphoramidite chemistry require rigorous process control to minimize risks of sequence truncation, misfolding, and contamination.

GMP frameworks provide guardrails across every step of manufacturing, from in-process testing and cleanroom monitoring to final product release. Batches that fail to meet established criteria are quarantined and investigated to ensure that only materials meeting the highest quality standards move forward.

As TIDES therapies progress into later-stage trials or commercial use, the complexity and scale increase. Maintaining consistency while scaling production requires large-scale reactors, high-throughput purification technologies, and validated controls. A manufacturer’s ability to uphold GMP at scale is a key success factor.

Quality Assurance and Compliance You Can Trust

At CPC Scientific, quality is built into every stage of manufacturing. Our QA team ensures full compliance with SOPs and batch documentation, while QC performs extensive analytical testing before any material is released. Cleanroom conditions, equipment calibrations, and data integrity are continuously monitored to maintain traceability and GMP alignment.

Our track record speaks to our standards. Our group has passed inspections by the FDA, EMA, TGA, MFDS, and NMPA, and holds ISO 9001 and ISO 13485 certifications. With nearly 25 years in the field, we understand regulatory expectations and consistently meet or exceed them.

Scalable Manufacturing Without Compromise

Our group’s Hangzhou GMP facility spans 26,000 square meters, with 19 synthesis and 16 purification lines. It supports over 1,000 kilograms of peptide API annually, with individual batch sizes exceeding 25 kilograms. We also support GMP-grade oligonucleotide production ranging from 1 to 17 kilograms annually.

In the United States, our new Rocklin, California site (41,000 square feet) will be operational in 2026, adding several hundred kilos per year of peptide capacity and offering a U.S.-based supply chain solution. This added flexibility supports clients and partners with the geographic diversity needed for dependable global supply.

Partner with CPC Scientific for Excellence

GMP manufacturing is the critical link between scientific innovation and clinical reality. For peptide and oligonucleotide therapies, where complexity is high and patient impact is real, partnering with an experienced GMP manufacturer is essential.

With over two decades of proven excellence, CPC Scientific has empowered our clients to accelerate hundreds of innovative new chemical entities into GMP development. More than 300 active pipelines from preclinical studies to Phase III trials reflect our commitment to driving scientific breakthroughs.

At CPC Scientific, we offer the expertise, infrastructure, and regulatory credibility to move your program forward with confidence and compliance. Contact us to discuss how we can support your therapeutic goals and bring your innovation to life.

References

Al Musaimi, O., AlShaer, D., de la Torre, B. G., & Albericio, F. (2025). 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 18(3), 291. https://doi.org/10.3390/ph18030291

DeCollibus, D. P., Searcy, J., Tivesten, A., Akhtar, N., Lindenberg, C., Abarrou, N., … Storch, K. (2023). Considerations for the terminal sterilization of oligonucleotide drug products. Nucleic Acid Therapeutics, 33(3), 159–177. https://doi.org/10.1089/nat.2022.0073

Medicines and Healthcare products Regulatory Agency. (2018, March). GxP data integrity guidance and definitions. https://assets.publishing.service.gov.uk/media/5aa2b9ede5274a3e391e37f3/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf

Rossino, G., Onesto, V., Pavan, S., Terenzi, A., D’Andrea, F., & D’Ursi, A. M. (2023). Peptides as therapeutic agents: Challenges and opportunities in the green transition era. Molecules, 28(20), 1703. https://www.mdpi.com/1420-3049/28/20/7165

Vinjamuri, B. P. (2024). A review on commercial oligonucleotide drug products. International Journal of Pharmaceutics. Advance online publication. https://doi.org/10.1016/S0022-3549(24)00152-7

Resources

Click on CPC Scientific News and Articles to see latest News & Events.